Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia

This publication has 92 references indexed in Scilit:

• BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996)
  Leukemia, 2002
• The Children Leukemia Group: 30 years of research and achievements
  European Journal Of Cancer, 2002
• A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
  Nature, 2001
• Effects of the Antifungal Agents on Oxidative Drug Metabolism
  Clinical Pharmacokinetics, 2000
• The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics
  Environmental Health Perspectives, 1997
• Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms
  Pharmacogenetics, 1996
• Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
  European Journal Of Cancer, 1996
• A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
  Nature Genetics, 1995
• Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
  The Journal of Pediatrics, 1991
• Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
  New England Journal of Medicine, 1986